ELEVATED GALECTIN-3 DOES NOT PREDICT BENEFIT FROM MINERALOCORTICOID RECEPTOR ANTAGONIST USE IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION
Publication
, Conference
Gandhi, PU; Motiwala, S; Belcher, A; Gaggin, H; Weiner, R; Baggish, A; Fiuzat, M; Rocca, H-PB-L; Januzzi, J
Published in: Journal of the American College of Cardiology
March 2015
Duke Scholars
Published In
Journal of the American College of Cardiology
DOI
ISSN
0735-1097
Publication Date
March 2015
Volume
65
Issue
10
Start / End Page
A970 / A970
Publisher
Elsevier BV
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Gandhi, P. U., Motiwala, S., Belcher, A., Gaggin, H., Weiner, R., Baggish, A., … Januzzi, J. (2015). ELEVATED GALECTIN-3 DOES NOT PREDICT BENEFIT FROM MINERALOCORTICOID RECEPTOR ANTAGONIST USE IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION. In Journal of the American College of Cardiology (Vol. 65, pp. A970–A970). Elsevier BV. https://doi.org/10.1016/s0735-1097(15)60970-6
Gandhi, Parul U., Shweta Motiwala, Arianna Belcher, Hanna Gaggin, Rory Weiner, Aaron Baggish, Mona Fiuzat, Hans-Peter Brunner-La Rocca, and James Januzzi. “ELEVATED GALECTIN-3 DOES NOT PREDICT BENEFIT FROM MINERALOCORTICOID RECEPTOR ANTAGONIST USE IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION.” In Journal of the American College of Cardiology, 65:A970–A970. Elsevier BV, 2015. https://doi.org/10.1016/s0735-1097(15)60970-6.
Gandhi PU, Motiwala S, Belcher A, Gaggin H, Weiner R, Baggish A, et al. ELEVATED GALECTIN-3 DOES NOT PREDICT BENEFIT FROM MINERALOCORTICOID RECEPTOR ANTAGONIST USE IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION. In: Journal of the American College of Cardiology. Elsevier BV; 2015. p. A970–A970.
Gandhi, Parul U., et al. “ELEVATED GALECTIN-3 DOES NOT PREDICT BENEFIT FROM MINERALOCORTICOID RECEPTOR ANTAGONIST USE IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION.” Journal of the American College of Cardiology, vol. 65, no. 10, Elsevier BV, 2015, pp. A970–A970. Crossref, doi:10.1016/s0735-1097(15)60970-6.
Gandhi PU, Motiwala S, Belcher A, Gaggin H, Weiner R, Baggish A, Fiuzat M, Rocca H-PB-L, Januzzi J. ELEVATED GALECTIN-3 DOES NOT PREDICT BENEFIT FROM MINERALOCORTICOID RECEPTOR ANTAGONIST USE IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION. Journal of the American College of Cardiology. Elsevier BV; 2015. p. A970–A970.
Published In
Journal of the American College of Cardiology
DOI
ISSN
0735-1097
Publication Date
March 2015
Volume
65
Issue
10
Start / End Page
A970 / A970
Publisher
Elsevier BV
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology